Yesterday we took you through how Merck is shifting away from COVID mitigation to declare war on cancer.
A similar theme is developing all over the pharmaceutical industry as other big players move on from high-intensity COVID treatments and begin the long work of establishing new growth plays.
For today's update, Eli Lilly ($LLY) has been deep in that transition for well over a year as they have gotten key approvals for their once-in-a-generation treatment: Mounjaro.
The earnings report we got last week from LLY was really encouraging as it showed better and better trial data for Mounjaro, as well as a strong pathway toward regulatory approval for obesity.
Right now, Mounjaro is the single most popular treatment ever in its class, and that's ONLY with approvals for type 2 diabetes.
With off-label prescriptions now harder to acquire after a coupon program expired in April, regulatory approval for various obesity applications is exactly what LLY needs to get Mounjaro to as many patients as possible.
But this isn't just about LLY's ongoing war on America's biggest health crisis via obesity, it's also about expanded treatment options for a wide range of other disorders.
Eli Lilly's Alzheimer's treatment looks set for approval, and revenues are poised to pop once their biggest cancer treatment receives a big new approval.
There's really nothing new here at Eli Lilly, everything we've been talking about for the last year is simply accelerating -- which necessitates a new price target on our end.
We're at the beginning of a long process here, so let's try to make this quick and give you the details you need: 👇